US Serial No. 10/773,256 Applicant's Docket No. Procaps 002C1

-- IN THE CLAIMS --

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-12. (canceled)

13. (currently amended) _ A pharmaceutical formulation for oral administration having increased stability and bioavailability consisting essentially of a soft gelatin capsule which contains a therapeutically active amount of a Cox2 inhibitor dissolved in a composition consisting essentially of: 40% to 80% by weight glycofurol; 15% to 35% by weight of glycerin; 5% to 15% by weight water.

14. (previously presented) The formulation of claim 13 wherein said Cox 2 inhibitor is rofecoxib.

15. (<u>previously presented</u>) The formulation of claim 13 wherein said Cox 2 inhibitor is valdecoxib.

16. (previously presented) The formulation of claim 13 wherein said Cox 2 inhibitor is celecoxib.

US Serial No. 10/773,256 Applicant's Docket No. Procaps 002C1

17. (previously presented) The formulation of claim 13 wherein said Cox 2 inhibitor is parecoxib.